Select patented drugs to be included in India's NLEM?

27 November 2020

An intense debate is going on in India on whether patented drugs should be selected and identified for inclusion in the National List of Essential Medicines (NLEM) 2020, which is being finalized by the Expert Committee constituted by the Ministry of Health.

The increasing burden of cancer and rare diseases, as well as the high cure rate now being achieved by patented drugs especially in the treatment of cancer, are adding to the claim for inclusion.

At a virtual National Consultation Stakeholders meeting, industry stakeholders highlighted the long term remission that has been observed when a disease is treated with new patented drugs, in addition to cure.

Unprecedented increase in API prices

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK